Christopher Austin, Vesalius CEO

Months af­ter launch­ing with lofty goal, Flag­ship start­up stream­lines ops, chops head­count

Even by Flag­ship Pi­o­neer­ing’s stan­dards, the stat­ed goal at Vesal­ius Ther­a­peu­tics — un­veiled at its launch this March — was ex­ceed­ing­ly am­bi­tious. Armed with $75 mil­lion in Se­ries A fund­ing, the start­up was out to “rev­o­lu­tion­ize the treat­ment of the dis­eases that dri­ve nine­ty per­cent of hu­man ill­ness.” It would, as CEO Christo­pher Austin ex­plained, de­ploy cut­ting-edge tech­nol­o­gy to look for un­der­ly­ing caus­es for a dizzy­ing ar­ray of com­mon dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.